VolitionRX Ltd (VNRX) is an esteemed multinational company in the biotechnical field, primarily dealing with scientific research and medicinal development. Listed on NYSE American, it is headquartered in Isnes, Belgium, with additional operations in Texas, U.S., and Singapore. It's an innovative life sciences company committed to make a significant impact on global health through the introduction of its groundbreaking technology and products.
Founded in 2010, VolitionRX has created a niche for itself in the market by developing diagnostic tests for cancer and other diseases, utilizing its proprietary Nucleosomics® technology platform. The company collects and analyzes nucleosomes, structures in the blood that contain DNA, to indicate the presence of specific diseases. Its intention is to deliver cost-effective products that can help in early diagnosis and save lives.
The core vision of the company is to make its blood-tests as universal and regular as cholesterol tests are today. It believes in aiding doctors through simple and easy-to-use tests that can detect malignant diseases in their early stages. In cancer diagnostics, in particular, early detection is key, and it is here that VNRX aims to make the biggest impact.
In recent years, the company has released Nu.Q™ products, a line of research-use-only products for academics, pharmaceutical companies, and for research into multi-cancer screening. The company believes that Nu.Q can become a leading non-invasive, regular screening test for adults, specifically for detecting colorectal cancer – one of the most commonly diagnosed cancer types worldwide.
VolitionRX prides itself on its dedicated team of professionals who continuously strive to understand and tap into the nuances of epigenetics and disease diagnosis. With an unwavering commitment to improving global health, the company is proactively involved in numerous research projects and clinical trials worldwide.
VNRX has experienced steady growth over the years, proving its resilience in an industry marked by rapid change and fierce competition. Although the company is still relatively young, it has proven its capability to innovate and adapt, cementing its future in the biotech industry.
While VNRX is primarily known for its groundbreaking work in cancer detection, the company's R&D initiatives extend beyond this. They are also working towards the detection of other diseases such as infectious and autoimmune diseases. This versatility affirms that VolitionRX Ltd is not only a pioneer in biotech innovation but also a versatile player in the field of medical testing and research.